52w high/low | ₹3014.95 / ₹1303.6 |
P/E ratio | 119.4 |
Dividend | 0.79 |
ROE | 3.93 |
ROCE | 4.6 |
Face value | 2 |
Book value | ₹965.31Cr |
Market capital | ₹28,402.3Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
Piramal Enterprises Limited (PEL), erstwhile Piramal Healthcare Limited, is the flagship company of the Piramal Group, led by Ajay Piramal. Piramal Enterprises Limited (PEL) is one of India's large diversified companies, with a presence in Financial Services, Pharmaceuticals and Healthcare Insights & Analytics. The company derived around 46% of its revenue from outside India during the financial year ended 31 March 2018. In Pharma, through an end-to-end manufacturing capabilities across 13 global facilities and a large global distribution network to over 100 countries, PEL sells a portfolio of niche differentiated Pharma products and provides an entire pool of Pharma services (including in the areas of injectable, HPAPI etc. ). PEL's Global Pharma business has a strong product portfolio of niche differentiated branded generic products that are difficult to manufacture, sell or distribute. PEL's Contract Development and Manufacturing Organisation (CDMO) services segment offers end-to-end solutions across the drug life cycle through a globally integrated network of facilities. PEL's India consumer products division caters to the Indian self-care market.